Teva Pharmaceutical Industries Limited (NYSE:TEVA) :The total money flow, which is calculated as the dollar value of composite uptick minus downtick trades was negative ($16.88 million) and the uptick to downtick ratio was 0.73. The transaction value on upticks was $46.44 million and on downticks, the transaction value was $63.32 million. In block trades, the transaction value of inflow done during uptick was $20.56 million. The transaction value of block trades during downticks was $39.38 million. The uptick to downtick block trade ratio was 0.52. The money flow was negative ($18.82 million), indicating the traders were booking profit on the price strength. Teva Pharmaceutical Industries Limited (NYSE:TEVA) rose $0.66 at $50.23, during intraday Wednesday , a rise of 1.33% over the previous days close.
Currently the company Insiders own 7.1% of Teva Pharmaceutical Industries Limited shares according to the proxy statements. Institutional Investors own 64.03% of Teva Pharmaceutical Industries Limited shares.
The company shares have dropped -18.67% from its 1 Year high price. On Jul 28, 2015, the shares registered one year high at $72.31 and the one year low was seen on Jun 27, 2016. The 50-Day Moving Average price is $51.95 and the 200 Day Moving Average price is recorded at $56.91. Teva Pharmaceutical Industries Limited (NYSE:TEVA): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $50.00 and $49.86 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $50.56. The buying momentum continued till the end and the stock did not give up its gains. It closed at $50.26, notching a gain of 1.39% for the day. The total traded volume was 5,417,351 . The stock had closed at $49.57 on the previous day.
Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.